Phenotyping Protocols for Pipeline: UCD late adult UCDLA_001

Unrestricted

Welfare Observations UCDLA_WEL_001 (v.1.0)

The Welfare Observations procedure is used for the recording of welfare issues as and when they occur.

Body Weight UCDLA_BWT_001 (v.1.0)

The body weight test measures the weight of the mouse in a time series, allowing monitoring of its evolution; also, it is required in many other procedures.

Week 52

Grip Strength UCDLA_GRS_001 (v.1.0)

The grip strength test is used to measure the neuromuscular function as maximal muscle strength of forelimbs and combined forelimbs and hind limbs. These are assessed by the grasping applied by the mouse on a grid that is connected to a sensor. Three trials are carried out in succession measuring forelimb-strength only, followed by three successive trials measuring the combined forelimb/hindlimb grip strength. All grip strength values obtained are normalized against mouse body weight.Ontological description: MP:0001515 - abnormal grip strength.

Combined SHIRPA and Dysmorphology UCDLA_CSD_003 (v.3.9)

SHIRPA and dysmorphology were originally always separate assessments.  However they have recently been combined as assessments, so that they take place at the same time.The purpose of the assessments is to examine mice for obvious physical characteristics, behaviors and morphological abnormalities.Descriptions include abnormal locomotion/appearance/behavior/reflex reactions.

Week 55

Electrocardiogram (ECG) UCDLA_ECG_003 (v.3.0)

To provide a high throughput method to obtain Electrocardiograms in a conscious mouse or an anesthetized mouse.

Previous Versions:(v.2.6)

Week 56

Intraperitoneal glucose tolerance test (IPGTT) UCDLA_IPG_001 (v.1.0)

The glucose tolerance test measures the clearance of an intraperitoneally injected glucose load from the body. It is used to detect disturbances in glucose metabolism that can be linked to human conditions such as diabetes or metabolic syndrome. Animals are fasted for approximately 16 hours, fasted blood glucose levels are determined before a solution of glucose is administered by intra-peritoneal (IP) injection. Subsequently, the blood glucose level is measured at different time points during the following 2 hours.Ontological description: MP:0005559 - increased circulating glucose level, MP:0005560 - decreased circulating glucose level, MP:0005293 - impaired glucose tolerance, MP:0005292 - improved glucose tolerance, MP:0005291           abnormal glucose tolerance, MP:0000188 - abnormal circulating glucose level.

Week 57

X-ray UCDLA_XRY_001 (v.1.0)

Construct and analyse digital X-ray images in immobilised mice using a Faxitron X-Ray system or NTB digital X-ray scanner.

Body Composition (DEXA lean/fat) UCDLA_DXA_001 (v.1.0)

Measure bone mineral content and density as well as body composition in mice using the DEXA (Dual Energy X-ray Absorptiometry) analyser.

Week 58

Eye Morphology UCDLA_EYE_003 (v.3.0)

To detect abnormalities in eye morphology.

Previous Versions:(v.2.8)

Week 59

Tissue Embedding and Block Banking UCDLA_BLK_001 (v.1.9)

Collect and fix a standard list of tissues from the complete necropsy (see IMPC Gross Pathology & Tissue Collection SOP)Trim the fixed tissues into cassettes for processingEmbed the tissues in paraffin in a standard orientation

Clinical Chemistry UCDLA_CBC_003 (v.3.9)

Clinical chemistry determines biochemical parameters in plasma including enzymatic activity, specific substrates and electrolytes. Ontological description: MP:0001545 – blood physiology abnormalities.

Gross Pathology and Tissue Collection UCDLA_PAT_002 (v.2.9)

To perform a complete necropsy to detect and record abnormal external findings and macroscopic alterations in internal and external organs, record body and heart weights (see IMPC Heart Weight SOP), and collect a standardized list of tissues for fixation with or without further processing (see non-mandatory IMPC Tissue Embedding & Block Banking SOP).

Hematology UCDLA_HEM_002 (v.2.9)

Hematological assessment of blood determines blood cell counts (white blood cells, red blood cells, hemoglobin, and platelets) and additional hematological parameters (hematocrit, mean cell volume, mean corpuscular hemoglobin, mean cell hemoglobin concentration) can be derived using these indices. These tests will indicate abnormalities in the production of blood and its components (blood cells and hemoglobin) as well as in the associated blood-forming organs. Ontological description: MP:0002429 - abnormal blood cell morphology/development.

Heart Weight UCDLA_HWT_001 (v.1.9)

To evaluate cardiac size using heart weight and body weight.

Immunophenotyping UCDLA_IMM_002 (v.2.0)

Immunophenotyping of immune system cells

Previous Versions:(v.1.0)